Background Although approximately 50% of heart failure patients are reported as heart failure with preserved left ventricular systolic function (HFPSF), echocardiographic prognostic predictors have not been well investigated. Recently, the tissue Doppler-derived index, the ratio of the early transmitral flow velocity and the early mitral annular velocity (E/E'), was reported as useful in predicting prognosis of patients with heart diseases. The purpose of this study was to investigate whether E/E' predicts prognosis in HFPSF. Methods and Results A total of 50 patients with HFPSF (ejection fraction >50%) were consecutively enrolled and studied. Echocardiographic examination was performed on admission and repeated after optimized medical therapy. Cardiac events were defined as death and unplanned hospitalization because of congestive heart failure. Cardiac event-free survival curves from patients with E/E' >15 and E/E' ≤15 at baseline did not differ. On the other hand, patients with E/E' >15 after medical therapy showed significantly lower cardiac event-free survival than patients with E/E' ≤15 (log-rank, P=0.005). By multivariate logistic regression analysis, E/E' >15 after medical therapy was the only independent predictor of cardiac events (P=0.037, risk ratio=6.1, 95% confidence interval: 1.12-33.3) in patients with HFPSF. Conclusions Elevated E/E' after optimized medical therapy may be useful in predicting cardiac events in patients with HFPSF. (Circ J 2009; 73: 86 -91) 
t has been previously reported that approximately onethird of patients with congestive heart failure (CHF) have preserved left ventricular (LV) systolic (S) function. 1 However, the incidence of heart failure with preserved LV S function (HFPSF) has recently increased and now comprises nearly 50% of CHF patients. [2] [3] [4] [5] Despite the increased incidence and importance of the HFPSF, no prognostic indicators have been reported. Doppler echocardiographic indices have been reported as prognostic predictors in patients with impaired LV S function. [6] [7] [8] [9] In particular, the Doppler-derived diastolic (D) index, the deceleration time of the early transmitral flow velocity, has been reported as a correlate of LV filling pressure and thus, a prognostic predictor of patients with S dysfunction. Recently, the ratio of the early transmitral flow velocity and the early mitral annular velocity (E/E') by tissue Doppler imaging (TDI) technique has been proposed as an index of LV filling pressure and therefore a strong predictor of the prognosis of patients with various cardiac diseases. [10] [11] [12] [13] [14] [15] We hypothesized that E/E' would predict prognosis in patients with HFPSF, so we undertook the present study to investigate whether it does.
Methods

Study Populations
Between January 2000 and May 2006, patients with HFPSF who had an echocardiographic examination on admission and at follow-up at the Bell Land General Hospital (Sakai, Japan) were enrolled in this study. Patients with CHF were diagnosed as HFPSF if (1) LV ejection fraction (EF) >50%, (2) significant (>moderate) mitral or aortic valvular disease was not present and (3) non-cardiogenic etiologies of pulmonary congestion, such as renal failure, severe anemia or adult respiratory distress syndrome, were excluded. A total of 50 consecutive patients with HFPSF were identified (23 males, 27 females; mean age 77±11 years). B-type natriuretic peptide (BNP) level was measured in a subset of patients.
Echocardiographic Examination
Within 24 h of admission, conventional transthoracic 2-dimensional and Doppler echocardiography were performed with patients in the left lateral decubitus position using a commercially available echocardiographic machine (GE medical, Vivid 7, Milwaukee, WI, USA) that had a broadband (1.5-4 MHz) phased array transducer. From the parasternal long-axis view, the left atrial dimension was measured as reported previously. LV end-D volume (EDV), end-S volume (ESV) and EF were measured and calculated by modified Simpson's rule from the apical 2-and 4-chamber views. 16 LV mass index was also calculated. 17 Transmitral flow velocity signals were recorded from the 
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Failure Patients With Preserved Systolic Function apical 4-chamber view and the early (E) and late (A) transmitral flow velocities were measured. Deceleration time (DT) of the E was also measured. Similarly, pulmonary venous flow velocity signals were recorded from the apical 4-chamber view. S and D peak velocities were measured and the ratio of S to D (S/D) was calculated.
TDI Measurement
The apical 4-chamber view was used to obtain the TDI of the mitral annulus. A sample volume of the pulsed-wave Doppler was positioned at the septal side of the mitral annulus and then the spectral signal of the mitral annular velocity was recorded. The peak early (E') mitral annular velocity was measured and E/E' was calculated as E divided by E'. 15 These echo-Doppler measurements were performed on admission in all patients. Patients were divided into 2 groups according to the baseline E/E' value: E/E' >15 and E/E' ≤15.
Echocardiographic Follow-up
Echocardiographic data obtained after optimized medical therapy were also analyzed. Patients were divided into 2 groups according to the E/E' value after medical therapy: E/E' >15 and E/E' ≤15. 
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Clinical Outcome Cardiac events were defined as death and unplanned hospitalization because of CHF. Each event was identified by medical record review or telephone contact.
Statistical Analysis
Continuous data are expressed as mean ± SD or median with interquartile range (IQR), depending on the distribution of the variable. The differences between 2 groups for the parametrical data were tested by unpaired t-test or the Mann-Whitney U-test. Categorical variables between 2 groups were compared using the chi-square test or Fisher's exact test. Independent predictors of cardiac events were calculated by logistic regression. The univariate variables with a probability value <0.10 were identified and entered into a multivariate logistic regression analysis. Cumulative survival curves during follow-up in patients with lower (≤15) vs higher (>15) E/E' at baseline and at follow-up were obtained by the Kaplan-Meier method with a log-rank test. Significance was set at P<0.05. Statistical analysis was performed using commercially available software (Statview, Abacus Concepts, Calabasus, CA, USA).
Results
Baseline clinical characteristics of the patients with E/E' >15 and E/E' ≤15 at baseline are shown in Table 1 . There were no significant differences between the groups. Baseline echocardiographic data at the time of the initial hospitalization are also summarized in Table 1 . Patients with E/E' >15 at baseline had significantly higher E, A, E/A, E/E' and lower E' values.
During the follow-up period (mean 564 days), 8 deaths (16%) and 18 CHF (36%) were documented. Cardiac events occurred in 20 patients (40%). The Kaplan-Meier plot of cardiac event-free survival rate during follow-up did not show differences between patients with E/E' >15 and those with E/E' ≤15 at baseline (log-rank, P=0.786). By univariate and multivariate analysis, no baseline echocardiographic predictors could be identified. Table 2 shows the clinical characteristics and medications of patients with E/E' >15 and E/E' ≤15 after optimized medical therapy. No significant difference was found between the 2 groups. Echocardiographic indices at baseline and after medical therapy are shown in Table 3 . Patients with E/E' >15 after medical therapy had significantly lower E' and higher E/E' value at baseline and significantly higher E, lower E' and higher E/E' value after medical therapy. BNP was measured in 19 patients and the level was significantly higher in patients with E/E' >15 after medical therapy than in those with E/E' ≤15 (median, 333.0 pg/ml [IQR, 164.8-665.8 pg/ml] vs median, 92.8 pg/ml [IQR, 35.5-328.0 pg/ml]; P=0.04). Functional and hemodynamic changes after medical therapy are summarized in Table 4 . New York Heart Association functional class improved, S and D blood pressures were lowered and heart rate decreased after medical therapy.
Patients with E/E' >15 after medical therapy had a significantly higher incidence of unplanned hospitalization because of CHF (50% vs 15 %, P=0.01) and a trend toward a higher mortality rate (23% vs 5%, P=0.08) ( Table 5) . As a result, patients with E/E' >15 after medical therapy had a significantly higher incidence of cardiac events (57% vs 15%, P=0.003). The Kaplan-Meier plot of cardiac event-free sur- vival rate during follow-up was significantly lower in patients with E/E' >15 than in patients with E/E' ≤15 after medical therapy (log-rank, P=0.005; Fig 1) . By univariate analysis, E/E' >15, E', EDV, ESV and EF (all after medical therapy) were predictors (P<0.10) of cardiac events. Neither clinical characteristics nor medications were univariate predictors of cardiac events. By multivariate logistic regression analysis, E/E' >15 after medical therapy was the only independent echocardiographic predictor of cardiac events (P=0.037, chi-square=4.36, risk ratio=6.1, 95% confidence interval: 1.12-37.3).
Discussion
Our present study showed that baseline echocardiographic indices, including E/E', did not predict subsequent cardiac events in patients with HFPSF. However, elevated E/E' after optimized medical therapy was an independent echocardiographic predictor of subsequent cardiac events in patients with HFPSF.
Echocardiographic investigations have shown that LVEF and ESV are predictors of mortality and morbidity in patients with S dysfunction. 18 In addition to the S indices, LV D indices such as E/A and DT have been shown to predict mortality in patients with S dysfunction. [6] [7] [8] Although many echocardiographic investigations have been reported with respect to the echocardiographic predictors of prognosis in patients with impaired LV S function, the echocardiographic predictors of HFPSF have not been fully investigated.
Recent epidemiological and clinical studies have consistently demonstrated that the proportion of HFPSF among patients with CHF has increased from 30% to 50%. 5, 19 It has been reported that HFPSF is most prevalent among elderly women, as in our study population (mean age was 77 years and 54% females). Additionally, although aging, hypertension, ischemic heart disease and diabetes (or impaired glucose tolerance) are known contributors to the development of D dysfunction, the exact relationship between these factors and the development of D dysfunction has not been elucidated. 20, 21 In our study population, 68% of the patients had hypertension, 26% had diabetes and 12% had a history of myocardial infarction. Furthermore, the prognosis of HFPSF patients has been reported as similar to or marginally better than CHF patients with decreased LV S function. 5, 19, 22 Although the prognosis of the patients with S heart failure has improved consistently as a result of progress in medical therapy, such as β-blockers, angiotensin-converting enzyme inhibitors (ACEIs) and statins, the prognosis of patients with HFPSF has not shown a remarkable improvement during the past decade or so. 5 In fact, only limited data have shown improvements of the survival in patients with HFPSF by specific medical treatments. [23] [24] [25] [26] This may be explained in part by the fact that no prognostic predictors or indices to evaluate the efficacy of treatments 27 in patients with HFPSF. Recently, the tissue Doppler-derived index, E/E', has been developed as a correlate of LV filling pressure or pulmonary capillary wedge pressure. 10, 11 Additionally, E/E' has been shown to predict prognosis of patients with various cardiac diseases. 14, 15, 28, 29 Hills et al have shown that E/E' predicts LV remodeling and prognosis in patients with acute myocardial infarction. 14, 30 More recently, we demonstrated that E/E' predicted mortality of the non-valvular atrial fibrillation patients, irrespective of their S function. 15 
Fig 1.
Kaplan-Meier plot of event-free survival rate during follow-up in patients with early transmitral flow velocity and the early mitral annular velocity (E/E') ≤15 and patients with E/E' >15 after medical therapy. Interestingly, in our present study, deceleration time did not predict subsequent cardiac events in patients with HFPSF. This is a major difference compared with a previous report in patients with poor LV S function, in which deceleration time correlated negatively and linearly with LV filling pressure. 31 In patients with preserved LV S function, on the other hand, deceleration time does not correlate linearly with LV filling pressure, because the "normalappearing" transmitral flow velocity pattern among such patients both the "normal" and the "pseudonormal" patterns. 32 As reported previously, E' correlates negatively with tau, independent of LV filling pressure, and E correlates positively with LV filling pressure and negatively with tau. 10, 11 Accordingly, E/E' correlates with LV filling pressure in patients with both impaired and preserved S function. 10, 11 Patients with CHF, either S or D in origin, usually have an elevated LV filling pressure on admission and, therefore, it is possible that E/E' on admission does not distinguish those patients with a high likelihood of recurrence of CHF or death. However, in the present study patients with persistent elevated E/E', reflecting elevated LV filling pressure, after optimized medical therapy had a worse prognosis, which is in accordance with a previous report of patients with S dysfunction (EF ≤35%), where an reversible restrictive D filling pattern 6 months after optimized medical therapy was a strong predictor of favorable prognosis in patients with CHF. 33 In that report, a reversible restrictive D pattern in patients with S dysfunction reflected an improvement in the LV filling pressure after medical therapy. Similarly, a low E/E' value in patients with HFPSF may reflect an improvement in the LV filling pressure after medical therapy. 34 In the present study, 10 patients still had a pseudonormal or restrictive D filling pattern despite "optimized" medical therapy; the medical therapy for those particular patients may not have been optimal with respect to longterm outcome. In fact, 3 patients were not treated with diuretics, 3 not with ACEI/angiotensin-receptor blocker and 8 not with β-blockers. In addition, 3 of the 10 patients developed LV S dysfunction (EF <50%) during follow-up. Several investigators have suggested that patients with HFPSF do not necessary have normal S function. 35, 36 Our present result may have implications for the optimal medical therapy for patients with HFPSF. As mentioned, limited data are available with respect to the medical treatment of the HFPSF patients. Currently, several large-scale randomized trials targeting patients with HFPSF are underway. 37, 38 If the E/E' value could be used as a surrogate echocardiographic endpoint in patients with HFPSF, the efficacy of medical treatments could be tested and assessed with a smaller numbers of patients and shorter follow-up period. Furthermore, the BNP level has been shown to predict prognosis in patients with HFPSF, 39 so the combination of Doppler indices and BNP may have stronger predictive value in patients with HFPSF.
Study Limitations
First, direct measurement of the LV filling pressure was not performed, so it is uncertain whether E/E' truly reflects elevated LV filling pressure. Second, optimized medical treatment was given according to each primary physician's discretion, so this study itself does not address the therapeutic implications of some specific medical treatments on HFPSF.
In conclusion, elevated E/E' after optimized medical therapy predicted a worse clinical outcome in patients with HFPSF. The E/E' value may be a useful echocardiographic target of therapy in these patients.
